Milestone Pharmaceuticals Stock Forecast, Price & News

+0.07 (+1.28 %)
(As of 07/29/2021 01:07 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume1,713 shs
Average Volume77,877 shs
Market Capitalization$165.65 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive MIST News and Ratings via Email

Sign-up to receive the latest news and ratings for Milestone Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Milestone Pharmaceuticals logo

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. It is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as in the Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate, and other cardiovascular indications. Milestone Pharmaceuticals Inc. has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil in patients with paroxysmal supraventricular tachycardia and additional cardiovascular conditions in Greater China. The company was incorporated in 2003 and is headquartered in Montréal, Canada.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.71 out of 5 stars

Medical Sector

665th out of 2,214 stocks

Pharmaceutical Preparations Industry

340th out of 869 stocks

Analyst Opinion: 3.5Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Milestone Pharmaceuticals (NASDAQ:MIST) Frequently Asked Questions

Is Milestone Pharmaceuticals a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Milestone Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Milestone Pharmaceuticals stock.
View analyst ratings for Milestone Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Milestone Pharmaceuticals?

Wall Street analysts have given Milestone Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Milestone Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Milestone Pharmaceuticals?

Milestone Pharmaceuticals saw a drop in short interest during the month of June. As of June 30th, there was short interest totaling 230,800 shares, a drop of 30.5% from the June 15th total of 332,200 shares. Based on an average daily volume of 56,300 shares, the days-to-cover ratio is currently 4.1 days. Currently, 1.0% of the shares of the company are sold short.
View Milestone Pharmaceuticals' Short Interest

When is Milestone Pharmaceuticals' next earnings date?

Milestone Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for Milestone Pharmaceuticals

How were Milestone Pharmaceuticals' earnings last quarter?

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) announced its quarterly earnings data on Sunday, May, 16th. The company reported ($0.30) earnings per share for the quarter, topping analysts' consensus estimates of ($0.33) by $0.03.
View Milestone Pharmaceuticals' earnings history

How has Milestone Pharmaceuticals' stock price been impacted by Coronavirus?

Milestone Pharmaceuticals' stock was trading at $19.99 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MIST shares have decreased by 72.2% and is now trading at $5.55.
View which stocks have been most impacted by COVID-19

What price target have analysts set for MIST?

2 brokers have issued 1 year price targets for Milestone Pharmaceuticals' stock. Their forecasts range from $18.00 to $20.00. On average, they anticipate Milestone Pharmaceuticals' stock price to reach $19.00 in the next year. This suggests a possible upside of 242.3% from the stock's current price.
View analysts' price targets for Milestone Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Milestone Pharmaceuticals' key executives?

Milestone Pharmaceuticals' management team includes the following people:
  • Mr. Joseph G. Oliveto, CEO, Pres & Director (Age 53, Pay $646.38k)
  • Mr. Amit Hasija, CFO & Exec. VP of Corp. Devel. (Age 48, Pay $442.22k)
  • Dr. Francis Plat, Chief Medical Officer (Age 63, Pay $437.99k)
  • Dr. Philippe Douville, Founder, Strategic Advisor & Member of Scientific Advisory Board (Age 59)
  • Mr. Jeff Nelson, Chief Operating Officer
  • Dr. Philip T. Sager, Chief Medical Advisor & Member of the Scientific Advisory Board (Age 65)
  • Mr. Lorenz Muller, Chief Commercial Officer (Age 57)

Who are some of Milestone Pharmaceuticals' key competitors?

What other stocks do shareholders of Milestone Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Milestone Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), CymaBay Therapeutics (CBAY), iBio (IBIO), Allena Pharmaceuticals (ALNA), Fulcrum Therapeutics (FULC), OPKO Health (OPK), VYNE Therapeutics (VYNE), Soleno Therapeutics (SLNO) and Agile Therapeutics (AGRX).

When did Milestone Pharmaceuticals IPO?

(MIST) raised $75 million in an initial public offering on Thursday, May 9th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen and Piper Jaffray served as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

What is Milestone Pharmaceuticals' stock symbol?

Milestone Pharmaceuticals trades on the NASDAQ under the ticker symbol "MIST."

How do I buy shares of Milestone Pharmaceuticals?

Shares of MIST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Milestone Pharmaceuticals' stock price today?

One share of MIST stock can currently be purchased for approximately $5.55.

How much money does Milestone Pharmaceuticals make?

Milestone Pharmaceuticals has a market capitalization of $165.65 million. The company earns $-49,970,000.00 in net income (profit) each year or ($1.70) on an earnings per share basis.

How many employees does Milestone Pharmaceuticals have?

Milestone Pharmaceuticals employs 28 workers across the globe.

What is Milestone Pharmaceuticals' official website?

The official website for Milestone Pharmaceuticals is

Where are Milestone Pharmaceuticals' headquarters?

Milestone Pharmaceuticals is headquartered at 1111 DR. FREDERIK-PHILIPS BLVD SUITE 420, MONTREAL A8, H4M 2X6.

How can I contact Milestone Pharmaceuticals?

Milestone Pharmaceuticals' mailing address is 1111 DR. FREDERIK-PHILIPS BLVD SUITE 420, MONTREAL A8, H4M 2X6. The company can be reached via phone at 514-336-0444 or via email at [email protected]

This page was last updated on 7/29/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.